Basic Information
TELFAST D TABLET
TABLET, FILM COATED
Regulatory Information
SIN12071P
September 13, 2002
Pharmacy Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XR01BA52
Company Information
OPELLA HEALTHCARE SINGAPORE PTE. LTD.
OPELLA HEALTHCARE SINGAPORE PTE. LTD.
Active Ingredients
Strength: 120 mg
Strength: 60 mg
Detailed Information
Contraindications
**CONTRAINDICATIONS** TELFAST‐D is contraindicated in patients with known hypersensitivity to any of its ingredients. Due to its pseudoephedrine component, TELFAST‐D is contraindicated in patients with narrow‐angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment (see Drug Interactions section – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). It is also contraindicated in patients with severe hypertension, or severe coronary artery disease, and in those who have shown idiosyncrasy to its components, to adrenergic agents, or to other drugs of similar chemical structures. Manifestations of patient idiosyncrasy to adrenergic agents include: insomnia, dizziness, weakness, tremor, or arrhythmias.
Indication Information
**INDICATIONS** TELFAST‐D is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. Telfast‐D should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired.